"Boom! IMUNON’s ASCO survival data is *chef’s kiss* 💉—investors are piling in like it’s a Black Friday sale. The stock rocketed from $0.42 to $1.16 in a day (volume: *376M*?!), and the 9-period WMA just yeeted past the 21. RSI at 69? Warm, but not meltdown territory yet. Chart’s a rollercoaster, but that late-day surge to $1.55 screams FOMO. BUY the hype (but maybe pack a parachute). #BiotechBoom"

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.

Imunon, Inc. IMNN: 4.24 USD

Bullish views